Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV‐III antibodies to recombinant α‐interferon
J. A. McDonald, L. Caruso, P. Karayiannis, L. J. Scully, J. R. W. Harris, G. E. Forster, H. C. Thomas – 1 July 1987 – In a randomized controlled trial, 41 chronic hepatitis B virus carriers were allocated, by opening numbered computerized randomization envelopes, to receive recombinant interferon‐α2A at three different doses: 2.5; 5.0, and 10.0 mU per m2. Thirty‐two patients received treatment (6 for 3 months, 26 for 6 months), and 9 patients were controls (received no treatment). Ninety‐three per cent of our patients were homosexual, and 41% had anti‐HTLV‐III in their serum